Stock comparison
AdaptHealth
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AHCO
AdaptHealth
Market cap
$1.42B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AHCO | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 36D | 79B | HALO |
| Benjamin Graham | 21F | 83A | HALO |
| Philip Fisher | 26F | 65B | HALO |
| Peter Lynch | 30F | 53D | HALO |
| Joel Greenblatt | 24F | 40D | HALO |
| Charlie Munger | 27F | 80C | HALO |
| Terry Smith | 19F | 84A | HALO |
Side-by-side metrics
| Metric | AHCO | HALO |
|---|---|---|
| Market cap | $1.42B | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | 18.7x | 10.2x |
| ROIC (TTM) | 5.52% | 23.65% |
| Gross margin | 5.38% | 81.24% |
| Net margin | -2.78% | 23.13% |
| Revenue CAGR 5y | 7.23% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 1.3x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AHCO leads on
- P/E (TTM)-vs 24.0x+180%
HALO leads on
- Net margin23.13%vs -2.78%+112%
- Gross margin81.24%vs 5.38%+93%
- Market cap$8.1Bvs $1.42B+82%
- Revenue CAGR 5y33.23%vs 7.23%+78%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.